You are here

Solutions

Conference Summary: Using Lessons Learned from Previous Ebola Outbreaks to Inform Current Risk Management

CENTER FOR DISEASES CONTROL by Dickmann P, Kitua A, Kaczmarek P, Lutwama J, Masumu J, Karimuribo E, et al             April 8,2015 

Summary of conference on lessons learned from Ebola crisis

"...A major conclusion was that infectious disease management will work only when it is established with and within the community and not directed against it. This lesson requires community engagement in formulating infection control measures, as well as implementation, dissemination, and promotion of these measures. Infection control procedures are generally perceived as intrusive and, as such, often interfere with local social, cultural, and religious practices.... Building on this process of finding the right, appropriate containment measures, communication and health promotion work best when they involve community and religious leaders, traditional healers, and other advocates.

National and cross-border Ebola outbreaks are a new development, and engagement with various communities has presented a particular challenge throughout the current outbreak. A key aspect of this engagement is to devise and elaborate solutions for infection control that are consistent with local realities and practices. International health and aid organizations must strive to work in concert with communities to find adequate infection-control solutions....

Problem, Solution, SitRep, or ?: 

For Ebola patients, a way to see the faces of those helping

PUBLIC RADIO INTERNATIONAL  by Andrea Crossan                 April 7, 2015

...for those in hospitals suffering, all they see are masks and robot-looking suits of doctors and nurses caring for them. The medics must wear those protective suits to stop them from coming in contact with a patient. But some humanity is stripped away with the intimidating get-up.

Until now.

                      Jianjay Potter and Grace Zardon in Monrovia, Liberia.Credit: Marc Campos

Los Angeles-based artist Mary Beth Heffernan saw the Ebola suits on news reports. She thought about how isolating it was for the patients. And she came up with the idea of taking photos of health workers that could be attached to their protective clothing.

In late February, Heffernan travelled to Monrovia, Liberia to do just that.

She brought cameras, six printers, ink cartridges and sticky labels to print the photos on.

Problem, Solution, SitRep, or ?: 

Ebola Vaccine 2015: Guinea Seen As Best Hope For Preventative Drug Trials, But Time Is Running Out

INTERNATIONAL BUSINESS TIMES by Philip Roth       April 7, 2015

(Two stories. Scroll down)
Health officials’ best bet for discovering a vaccine for Ebola lies with the West African country of Guinea, where the outbreak that has killed an estimated 10,500 over the past year began, and the place that researchers largely ignored when it came time for drug trials. As researchers race to find a vaccine before the window of opportunity closes – essentially, before the epidemic is brought to an end -- scientists with the World Health Organization are beginning to test a vaccine in Guinea manufactured by researchers in the U.S. and Canada.

 

The race to find a vaccine for Ebola is in its final lap. Pictured, research assistant Georgina Bowyer works on a vaccine for Ebola at the Jenner Institute in Oxford, southern England, Jan. 16, 2015. Reuters

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Rhode Island Hospital Physician Comes Up With New Diagnostic Tool for Ebola Virus

news-medical.net - April 6, 2015

Adam C. Levine, M.D., an emergency medicine physician at Rhode Island Hospital and The Miriam Hospital who treated Ebola-infected patients in Liberia last year, used his field experience to create a tool to determine the likelihood that patients presenting with Ebola symptoms will actually carry the virus. His research was published in the Annals of Emergency Medicine today.

(READ COMPLETE ARTICLE)

CLICK HERE - RESEARCH - Derivation and Internal Validation of the Ebola Prediction Score for Risk Stratification of Patients With Suspected Ebola Virus Disease

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola Upsurge Could Undo Progress in Blink of an Eye, Warns Expert

‘Flare-ups occur and, frankly, before you can blink, we could be back to a situation where Ebola starts climbing up again,’ says the UN special envoy for Ebola, David Nabarro. Photograph: Salvatore Di Nolfi/EPA

UN special envoy for Ebola sounds cautionary note amid fears that individuals who ignore official advice could cause spike in infection rate

theguardian.com - by Sam Jones - March 26, 2015

Despite the massive push to bring the number of new Ebola cases down to zero as quickly as possible, there will inevitably be “flare-ups” that could reverse the overall downward trend and prove difficult to contain, the UN’s response co-ordinator has warned.

Dr David Nabarro, the UN’s special envoy for Ebola, said the huge medical, administrative and logistical operation to fight the disease could still be set back by individuals ignoring official advice. . . .

. . . “It’s [about] getting the full geographical coverage and linking everyone together with the most excellent data systems so the databases are comparable and we don’t end up with a mess because different people can’t talk to each other,” he explained.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Merck, NewLink Ebola vaccine appears safe, effective in new studies

REUTERS by Sharon Bagley                                                                      April 1, 2015

Early-stage trials of an experimental Ebola vaccine, two in the United States and four in Africa and Europe, have found that it appears to be safe and triggered robust production of Ebola-fighting antibodies, scientists reported on Wednesday.

Since trials cannot ethically expose volunteers to Ebola, the production of antibodies is a proxy for whether vaccines could prevent or even treat the disease.

The trials all tested a vaccine called VSV-ZEBOV, which was developed at the Public Health Agency of Canada and licensed to NewLink Genetics Corp and then to Merck & Co Inc. It consists of a cattle virus called rVSV that has been engineered to carry Ebola genes, which produce proteins meant to trigger production of anti-Ebola antibodies.

According to separate teams of scientists, that is what happened, two papers in the New England Journal of Medicine reported.

Read complete story.
http://www.reuters.com/article/2015/04/01/us-health-ebola-vaccine-idUSKBN0MS5DN20150401

Read NEW ENGLAND JOURNAL OF MEDICINE  papers

Problem, Solution, SitRep, or ?: 

App enables self-reporting of possible Ebola symptoms in Maryland

ASSOCIATED PRESS                                                                                     April 1, 2015

BALTIMORE — A Baltimore company and Maryland public health officials are announcing a smartphone and Web application for self-reporting possible Ebola symptoms.

Emocha Mobile Health Inc. said Wednesday that people returning from affected West African nations can use the app to report their temperature and any symptoms twice daily to the Department of Health and Mental Hygiene. The federal government recommends such reporting for 21 days.

The state health agency has operated a call center since October for monitoring people known to have been in affected countries. The app eventually will link to the state's database of such individuals to automate the reporting of data to Maryland and federal authorities.

Read more here:
 
 

 

Problem, Solution, SitRep, or ?: 

BioCryst gets HHS contract for Ebola drug development

CENTER FOR INFECTIOUS DISEASE RESEARCH AND POLICY by Lisa Schnerring               March 31, 2015

The US Department of Health and Human Services (HHS) announced today that it has awarded BioCryst Pharmaceuticals a $12 million grant to continue development of BCX4430, a small-molecule drug designed to treat Ebola and other filovirus infections, and to prepare for large-scale manufacturing of the agent.

Studies in nonhuman primates suggest that the drug is effective against Ebola and Marburg viruses and could be useful as a broad-spectrum antiviral, the HHS said in a statement. BCX4430 is currently in phase 1 human trials, and if results show safety, it could be one of the treatments to be tested for efficacy in clinical trials.

BCX4430 is the first small-molecule Ebola treatment that BARDA has supported. Other Ebola products in development that have received BARDA funding include the monoclonal antibody cocktail ZMapp and three vaccines.
Read complete story.
http://www.cidrap.umn.edu/news-perspective/2015/03/biocryst-gets-hhs-contract-ebola-drug-development

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Measures to safeguard schools in Ebola-hit Liberia point to need for continued vigilance

 When students returned to school in Liberia, they learned about the importance of good hygiene. Now they’re teaching others.

UNICEF BY  Tim Irwin                                         March 30, 2015

MONROVIA, Liberia, Classes at the Slipway primary school in central Monrovia resumed only a few weeks ago, but the new morning drill is already well established.

In Liberia, schools were closed for six months because of the Ebola epidemic. Now that class is back in session, students are following a new set of protocols to stave off infection with the deadly disease. Here, children queue to wash their hands before morning devotionals.

“We rub our palms together 10 times, wash between our fingers five times, around our thumbs five times and then scrub around our nails,” says Grace Winnie, who is in Grade 4.

Schools across Liberia reopened on 16 February, following a six-month closure because of the Ebola crisis. UNICEF has helped put in place new procedures aimed at minimizing the risk of infection.

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Solutions
howdy folks